GANX icon

Gain Therapeutics

2.61 USD
-0.03
1.14%
At close Feb 7, 4:00 PM EST
After hours
2.64
+0.03
1.15%
1 day
-1.14%
5 days
26.70%
1 month
14.98%
3 months
17.04%
6 months
174.02%
Year to date
12.50%
1 year
-45.05%
5 years
-76.70%
10 years
-76.70%
 

About: Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Employees: 32

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

151% more capital invested

Capital invested by funds: $3.89M [Q2] → $9.77M (+$5.88M) [Q3]

5.52% less ownership

Funds ownership: 12.08% [Q2] → 6.56% (-5.52%) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

32% less funds holding

Funds holding: 28 [Q2] → 19 (-9) [Q3]

73% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 11

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$7
168%
upside
Avg. target
$7.50
187%
upside
High target
$8
207%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Roth MKM
Boobalan Pachaiyappan
63% 1-year accuracy
5 / 8 met price target
168%upside
$7
Buy
Maintained
24 Dec 2024
HC Wainwright & Co.
Raghuram Selvaraju
42% 1-year accuracy
138 / 329 met price target
207%upside
$8
Buy
Reiterated
25 Nov 2024

Financial journalist opinion

Based on 3 articles about GANX published over the past 30 days

Neutral
GlobeNewsWire
3 days ago
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided the following letter to shareholders from the Company's President and CEO, Gene Mack:
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
Neutral
GlobeNewsWire
4 days ago
Gain Therapeutics To Participate in Upcoming Investor Conferences
BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Executive Officer of Gain, will present at two upcoming investor conferences:
Gain Therapeutics To Participate in Upcoming Investor Conferences
Positive
Zacks Investment Research
3 weeks ago
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy
Positive
Zacks Investment Research
1 month ago
Best Momentum Stocks to Buy for January 9th
GANX, FHB and TRV made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 9, 2024.
Best Momentum Stocks to Buy for January 9th
Positive
Seeking Alpha
1 month ago
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson's disease, with potential for substantial market impact and investor gains. The drug's ability to restore GCase function and its positive preclinical and Phase 1 results highlight its potential as a best-in-class treatment. Gain's aggressive development strategy and strong data sharing indicate confidence, with Phase 1b trial results expected by mid-2025, potentially increasing the company's valuation.
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Neutral
GlobeNewsWire
1 month ago
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease
The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT-02287 in people diagnosed with Parkinson's disease Phase 1b clinical trial follows successful Phase 1 study in which GT-02287 was safe and well tolerated while demonstrating GCase target engagement BETHESDA, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it has received approval in Australia to initiate a Phase 1b trial.
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease
Neutral
GlobeNewsWire
1 month ago
Gain Therapeutics To Present At Biotech Showcase 2025
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform
Gain Therapeutics To Present At Biotech Showcase 2025
Neutral
GlobeNewsWire
4 months ago
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson's Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson's Disease Models GT-02287 Prevents Tau Accumulation in a Cellular Model BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of new evidence supporting the disease-modifying activity of GT-02287 in preclinical animal models of both GBA-1 and idiopathic Parkinson's disease during a late-breaker poster session yesterday at the Society for Neuroscience (SfN) 2024 conference that is being held October 5-9 in Chicago, IL.
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
Neutral
GlobeNewsWire
4 months ago
Gain Therapeutics to Participate at Upcoming Investor Conferences
BETHESDA, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, interim Chief Executive Officer and current Chief Financial Officer of Gain, will participate in two upcoming investor conferences:
Gain Therapeutics to Participate at Upcoming Investor Conferences
Neutral
GlobeNewsWire
4 months ago
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
GT-02287 Increases Peripheral GCase Activity GT-02287 Demonstrates CNS Exposure Company to Host Webinar to Discuss Results at 8:30 AM ET Today BETHESDA, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of a late-breaking abstract at the International Congress of Parkinson's Disease and Movement Disorders.
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
Charts implemented using Lightweight Charts™